Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Connect Biopharma Holdings (CNTB) Capital Expenditures (2024 - 2025)

Connect Biopharma Holdings (CNTB) has disclosed Capital Expenditures for 2 consecutive years, with $16000.0 as the latest value for Q4 2025.

  • Quarterly Capital Expenditures fell 94.89% to $16000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $434000.0 through Dec 2025, down 42.13% year-over-year, with the annual reading at $434000.0 for FY2025, 42.13% down from the prior year.
  • Capital Expenditures hit $16000.0 in Q4 2025 for Connect Biopharma Holdings, down from $34000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $313000.0 in Q4 2024 to a low of $16000.0 in Q4 2025.